Chemo-radiation association in head and neck squamous cell carcinoma: Evidences and criticisms

Research output: Contribution to journalArticle

Abstract

Recently new strategies such as the association of chemotherapy with radiotherapy have emerged for the improvement of therapeutic outcome in the curative treatment of HNSCC: for patients with locally advanced HN-SCC, where outcome with radiotherapy alone is poor. More than one-hundred Phase III trials collected in large meta-analyses have showed that loco regional control and overall survival may be improved at high level of evidence by chemoradiotherapy especially if delivered with synchronous approach. Sequential or synchronous chemo-radiotherapy regimens can also play a crucial role in larynx-function preservation programs without the risk of overall survival reduction for patients with larynx or hypo pharynx tumors who are candidates to radical surgery. Recently, strong evidence for an improved outcome for high-risk resected patients has been shown by the use of adjuvant concomitant chemoradiotherapy. Despite hundreds of clinical trials in patients with advanced disease, there is no absolute consensus about patient selection for type of chemo-radiotherapy association, radiation or chemotherapy dose schedule. Nevertheless, awaiting for the results from ongoing trials where chemo-radiotherapy is explored in conjunction with new targeted therapies, many well-conducted clinical studies have expanded therapy options besides standard radiotherapy and have contributed to defining the evolving standard of care for patients with HNSCC.

Original languageEnglish
Pages (from-to)164-171
Number of pages8
JournalCurrent Drug Therapy
Volume5
Issue number3
DOIs
Publication statusPublished - 2010

Fingerprint

Radiotherapy
Radiation
Chemoradiotherapy
Larynx
Adjuvant Chemoradiotherapy
Drug Therapy
Survival
Therapeutics
Standard of Care
Pharynx
Patient Selection
Meta-Analysis
Carcinoma, squamous cell of head and neck
Appointments and Schedules
Clinical Trials
Neoplasms

Keywords

  • Chemotherapy
  • Head and neck squamous cell carcinoma
  • Radiotherapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{e5199da4d852422d80874038aeccc74d,
title = "Chemo-radiation association in head and neck squamous cell carcinoma: Evidences and criticisms",
abstract = "Recently new strategies such as the association of chemotherapy with radiotherapy have emerged for the improvement of therapeutic outcome in the curative treatment of HNSCC: for patients with locally advanced HN-SCC, where outcome with radiotherapy alone is poor. More than one-hundred Phase III trials collected in large meta-analyses have showed that loco regional control and overall survival may be improved at high level of evidence by chemoradiotherapy especially if delivered with synchronous approach. Sequential or synchronous chemo-radiotherapy regimens can also play a crucial role in larynx-function preservation programs without the risk of overall survival reduction for patients with larynx or hypo pharynx tumors who are candidates to radical surgery. Recently, strong evidence for an improved outcome for high-risk resected patients has been shown by the use of adjuvant concomitant chemoradiotherapy. Despite hundreds of clinical trials in patients with advanced disease, there is no absolute consensus about patient selection for type of chemo-radiotherapy association, radiation or chemotherapy dose schedule. Nevertheless, awaiting for the results from ongoing trials where chemo-radiotherapy is explored in conjunction with new targeted therapies, many well-conducted clinical studies have expanded therapy options besides standard radiotherapy and have contributed to defining the evolving standard of care for patients with HNSCC.",
keywords = "Chemotherapy, Head and neck squamous cell carcinoma, Radiotherapy",
author = "Renzo Corv{\`o} and Almalina Bacigalupo and Stefano Vagge",
year = "2010",
doi = "10.2174/157488510791561020",
language = "English",
volume = "5",
pages = "164--171",
journal = "Current Drug Therapy",
issn = "1574-8855",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Chemo-radiation association in head and neck squamous cell carcinoma

T2 - Evidences and criticisms

AU - Corvò, Renzo

AU - Bacigalupo, Almalina

AU - Vagge, Stefano

PY - 2010

Y1 - 2010

N2 - Recently new strategies such as the association of chemotherapy with radiotherapy have emerged for the improvement of therapeutic outcome in the curative treatment of HNSCC: for patients with locally advanced HN-SCC, where outcome with radiotherapy alone is poor. More than one-hundred Phase III trials collected in large meta-analyses have showed that loco regional control and overall survival may be improved at high level of evidence by chemoradiotherapy especially if delivered with synchronous approach. Sequential or synchronous chemo-radiotherapy regimens can also play a crucial role in larynx-function preservation programs without the risk of overall survival reduction for patients with larynx or hypo pharynx tumors who are candidates to radical surgery. Recently, strong evidence for an improved outcome for high-risk resected patients has been shown by the use of adjuvant concomitant chemoradiotherapy. Despite hundreds of clinical trials in patients with advanced disease, there is no absolute consensus about patient selection for type of chemo-radiotherapy association, radiation or chemotherapy dose schedule. Nevertheless, awaiting for the results from ongoing trials where chemo-radiotherapy is explored in conjunction with new targeted therapies, many well-conducted clinical studies have expanded therapy options besides standard radiotherapy and have contributed to defining the evolving standard of care for patients with HNSCC.

AB - Recently new strategies such as the association of chemotherapy with radiotherapy have emerged for the improvement of therapeutic outcome in the curative treatment of HNSCC: for patients with locally advanced HN-SCC, where outcome with radiotherapy alone is poor. More than one-hundred Phase III trials collected in large meta-analyses have showed that loco regional control and overall survival may be improved at high level of evidence by chemoradiotherapy especially if delivered with synchronous approach. Sequential or synchronous chemo-radiotherapy regimens can also play a crucial role in larynx-function preservation programs without the risk of overall survival reduction for patients with larynx or hypo pharynx tumors who are candidates to radical surgery. Recently, strong evidence for an improved outcome for high-risk resected patients has been shown by the use of adjuvant concomitant chemoradiotherapy. Despite hundreds of clinical trials in patients with advanced disease, there is no absolute consensus about patient selection for type of chemo-radiotherapy association, radiation or chemotherapy dose schedule. Nevertheless, awaiting for the results from ongoing trials where chemo-radiotherapy is explored in conjunction with new targeted therapies, many well-conducted clinical studies have expanded therapy options besides standard radiotherapy and have contributed to defining the evolving standard of care for patients with HNSCC.

KW - Chemotherapy

KW - Head and neck squamous cell carcinoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=78649288949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649288949&partnerID=8YFLogxK

U2 - 10.2174/157488510791561020

DO - 10.2174/157488510791561020

M3 - Article

AN - SCOPUS:78649288949

VL - 5

SP - 164

EP - 171

JO - Current Drug Therapy

JF - Current Drug Therapy

SN - 1574-8855

IS - 3

ER -